The company said it plans to launch two versions of the antigen test in the U.S. later this year: one version that's meant to be processed in a clinical laboratory and another that's portable and can be processed at point of care.
An employee works in a protective suit in a laboratory of the biotech company Qiagen in Germany, September 8, 2020.announced Tuesday that it plans to launch a new antigen test for the coronavirus that it says could eventually be deployed in airports and stadiums if it receives the appropriate authorizations.
"The portable test offers a new combination of speed and scale that marks an important step towards decentralized mass testing that health authorities all over the world have been urgently seeking," the company said in a release.
This test doesn't hold a candle to Pharmatech/Decision Diagnostics covidswiftkit antigen saliva and blood at-home tests that produce results in 10.5 seconds. FDA currently sitting on approval while other countries are placing orders for this.